Friday, November 27, 2015

CEO Andrew Witty says top GSK leaders did not know of China problems, committed to "rooting out" bad actors

GlaxoSmithKline CEO Andrew Witty said top leaders were not aware of allegedly illegal activity of executives in China, but the company was committed to rooting out corruption.

CEO Andrew Witty says top GSK leaders did not know of China problems, committed to "rooting out" bad actors

GlaxoSmithKline chief executive Andrew Witty at the drugmaker's new home at the Philadelphia Navy Yard. (Akira Suwa / Staff Photographer)

GlaxoSmithKline chief executive officer Andrew Witty said Wednesday that the head office in London was not aware of the activity of some of the company's executives in China, who have been accused of using travel agencies to pay off doctors and other health-care providers to increase sales of medicine.

In a conference call with reporters following the release of the GSK's second quarter financial results, Witty said the most recent China problem - and he said there were two distinct ones - allegedly involved some executives "defrauding" the company and the Chinese health care system.

"To see these allegations about people working for GSK is, as we've said, shameful," Witty said. "For me, personally, they are deeply disappointing. These allegations are totally contrary to our values. Outside and inside the company, people rightly expect us to operate with integrity. To be crystal clear, we have zero tolerance for this kind of behavior. We are absolutely committed to rooting out corruption."

GSK has more than 100,000 worldwide employees. About 1300 employees work out of the Philadelphia Navy Yard and others are in facilities in the suburbs of Pennsylvania and New Jersey.

In an earlier episode, a whistleblower reported problems with the company's China operations, though Witty said those were examined and not substantiated.

Recent reports from China-based correspondents for several news organizations suggest that executives from other major drug companies have been questioned in recent days.

Wednesday morning, Reuters reported that China's official Xinhua news agency said the government was trying to tackle "rampant" malpractice in the pharmaceutical sector, including corruption. Xinhua said 1,000 doctors, nurses and administrators at 73 hospitals in Zhangzhou city in the southeastern province of Fujian had been found taking kickbacks.

"It will not be surprising if more pharmaceutical companies and hospitals, domestic or international, are to be involved in probes in the days to come," Xinhua said in an English-language commentary without naming any firms or hospitals, according to Reuters. "Big international firms should shoulder (their) due responsibilities to bid farewell to malpractice, setting a good example and serving as a wake-up call for domestic pharmaceutical companies."

Drug companies, like other manufacturers, hope to sell products to China's 1.3 billion people, many of whom are making more money than they once did, but also developing chronic diseases (heart disease, diabetes, respiratory problems) at the rates seen in the United States and Europe. Like with those other industries, the drug market is often based on relationships between companies and government officials.

Witty said GSK is committed to working in China and beyond complying with whatever rules the government imposes, it will have to continually look at how the business operations need to change.

"It is clear to me that we are at an inflection point in what the Chinese marketplace is likely to look like in the future," Witty said, "not the least because of the Chinese government's desire to ensure its health-care system keeps up with the evolution of the country and the growing wealth across the country."

GSK's second-quarter financial statement is here.

Inquirer Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Inquirer Staff Writer
Also on
letter icon Newsletter